We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Progranulin and dementia -- a blood sample does not tell the full story
News

Progranulin and dementia -- a blood sample does not tell the full story

Progranulin and dementia -- a blood sample does not tell the full story
News

Progranulin and dementia -- a blood sample does not tell the full story

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Progranulin and dementia -- a blood sample does not tell the full story"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The key neurodegeneration protein progranulin is regulated differently in cerebrospinal fluid than in serum -


Progranulin is a central protein in both neuronal survival and neurodegenerative diseases. It is thus not surprising that altered progranulin levels represent a universal theme shared across several common neurodegenerative diseases. In Alzheimer's disease, for instance, reduced brain levels of progranulin contribute to the specific amyloid disease pathology, while increased levels appear to protect against this pathology. In genetic forms of another type of dementia, namely frontotemporal dementia (FTD), progranulin levels can be reduced. As progranulin can be measured relatively easily in blood, it seemed that a promising new biomarker for types of dementia has now been found. In fact, treatments were proposed to increase progranulin levels, aiming to yield a therapeutic effect for many neurodegenerative diseases. It was suggested to take progranulin in blood as a measure of response for these future treatments.


See Also: Epigenomics of Alzheimer’s disease progression


Carlo Wilke and Matthis Synofzik from the Hertie-Institute for Clinical Brain Research & German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany, have now shown that, unfortunately, the full story of progranulin is not that simple. The levels of progranulin in blood do not correlate with the levels of progranulin in the cerebrospinal fluid surrounding the brain—neither in Alzheimer's disease or in frontotemporal dementia, nor in amyotrophic lateral sclerosis (ALS). But it is the brain where these neurodegenerative diseases actually take place. It seems that the progranulin levels around the brain are regulated by different mechanisms than the progranulin levels in the body periphery, e.g. in blood.


These findings shed new light on the understanding of the biological processes underlying neurodegeneration in Alzheimer's Disease and other common neurodegenerative diseases. Moreover, they have important implications for clinical research and practice in these diseases: simply taking a blood sample for progranulin will not tell a lot about what happens to progranulin in the brain.


Learn More: Research discovers neuroprotective protein in blood is biomarker of Alzheimer's disease


These results maybe disappointing, at first glance, for researchers and pharmaceutical companies aiming to discover biomarkers and treatment measures but they prevent from working on possibly misleading biomarker and treatment trials. Such trials indeed need to focus, not on blood progranulin, but on central nervous progranulin.


Note: Material may have been edited for length and content. For further information, please contact the cited source.


Bentham Science Publishers


Publication

Wilke C et al. Serum Levels of Progranulin Do Not Reflect Cerebrospinal Fluid Levels in Neurodegenerative Disease. Current Alzheimer Research, Published 2016. doi: 10.2174/1567205013666160314151247


Advertisement